Allergan and Serenity receive FDA approval for Noctiva

6 March 2017

Dublin, Ireland-headquartered Allergan (NYSE: AGN) and American specialty pharmaceutical company Serenity Pharmaceuticals have received approval from the US Food and Drug Administration for Noctiva (desmopressin acetate).

The nasal spray, a treatment for nocturnal polyuria, a condition characterized by overproduction of urine at night, has been indicated for use by adults who awaken at least twice nightly for micturition.

The FDA approval is based on two randomized clinical trials involving over 1,000 patients which found more patients treated with desmopressin experienced at least half as many night-time urinations compared with those in the placebo group.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK